Anhedonia: Rebuilding the Reward System, Not Chasing Dopamine

Summary

Anhedonia, the loss of pleasure and interest, is a real, measurable, treatable reward-circuit problem rather than laziness or moral failure, and you rebuild it through behaviour and re-learning (graded reward exposure, savoring, exercise) and by cutting the supernormal-stimulus competition, NOT by "detoxing dopamine" or fasting a neurotransmitter that cannot be fasted.

Why Moderate

Moderate Evidence because the load-bearing claims sit on replicated RCT and meta-analytic support: anhedonia is a measurable, transdiagnostic reward-circuit deficit (neuroimaging meta-analysis plus a placebo-controlled agonist trial with target engagement), and behavioural activation, Positive Affect Treatment, and exercise move anhedonia or positive affect in RCTs. The dopamine-detox debunk is on firm neuroscience footing.

NOT Strong because key specifics are softer than the headline: the behavioural-for-anhedonia advantage was non-significant against an active comparator (the BATA null), pramipexole moved anhedonia more than broad depression rather than dissociating the two cleanly, the SSRI-blunting prevalence is survey-grade with contested attribution, and the supernormal-stimulus / "digital anhedonia" story is mechanistic rather than trial-proven. The entry refuses to inherit the strongest single result into a blanket claim.

NOT Emerging because this is not a handful of suggestive studies. The reward-circuit existence claim, the behavioural-treatment evidence, and the SSRI-underperformance pattern are each replicated across independent sources; only the supernormal-stimulus node and the blunting magnitude sit at the lower end, and the entry marks them as such rather than dragging the whole entry down.

Practical takeaway

The framing to hold: anhedonia is a reward circuit you rebuild, not a dopamine tank you drain and refill. The active ingredient is re-learning and reduced competition from artificial reward, not abstinence or "resetting."

The levers, highest-evidence first:
• Behavioural activation / graded reward exposure (do-before-you-feel). Schedule small, achievable, genuinely-once-rewarding activities and do them whether or not you feel like it; the feeling follows the action, not the other way round. Start tiny and build. (Protocol mechanics live in behavioural_activation_for_depression.)
• Savoring / positive-affect practice. Deliberately notice, prolong, and recall positive moments to strengthen the consummatory (liking) signal. Best used as an adjunct inside a structured plan, not as the whole plan; on its own its effect is small.
• Exercise. A low-cost, broadly effective mood lever, with the largest signals for more vigorous modalities (brisk walking or jogging, strength training, yoga). Treat it as a reliable foundation, not a guaranteed anhedonia-specific cure. (See exercise_for_mood_dose_response.)
• Reduce supernormal-stimulus load. Trimming endless-scroll feeds and on-demand hyper-reward is a reasonable, cheap experiment because it lowers the comparison bar for ordinary rewards. Frame it as "give ordinary pleasures a fair contest," NOT as "detox your dopamine." (See supernormal_stimuli_digital_recovery.)

The SSRI-and-blunting conversation: if your anhedonia or emotional flatness started or worsened after beginning an SSRI, that is a recognised, common possibility worth raising with your prescriber. Realised does not tell anyone to stop or change medication, and it refuses to let an iatrogenic cause go unnamed. Bring it to the person who prescribed it; do not act on it alone.

What NOT to do: do not run a "dopamine detox / dopamine fast" expecting your pleasure system to reset, that is not how the chemistry works. Do not treat "just savor more" or "just think positive" as a cure. Do not assume an SSRI will fix anhedonia by default; if reward is the dominant complaint, flag it specifically.

Escalate, do not self-manage, if: anhedonia is persistent or severe, you have lost interest in things that previously mattered for two weeks or more, or you have any thoughts of self-harm or that life is not worth living. Anhedonia is a leading predictor of suicidality. Behavioural self-help is an adjunct, never a substitute for professional care in moderate-to-severe depression.

Evidence detail

Why This Entry Exists

Anhedonia is the symptom people describe as "nothing feels good any more," and it is the one that most reliably predicts relapse, treatment dropout, and suicidality, yet it is routinely mislabelled as laziness, low motivation, or a character problem. At the same time the internet has converged on exactly the wrong fix: the "dopamine detox / dopamine fasting will reset your pleasure" story, which is neurochemically incoherent. You cannot fast a constitutive neurotransmitter, and abstaining from pleasure does not "reset" a receptor.

So this entry exists to hold two things at once. Anhedonia is a genuine, investigable reward-circuit dysfunction with real treatments, and the popular reset framing is a myth that monetises the despair. The treatments that work, behavioural activation and graded reward exposure, savoring and positive-affect practice, and exercise, work by reward re-learning and by lowering the comparison bar that supernormal stimuli have raised, not by draining and refilling a dopamine tank. The entry also names something patients are rarely warned about: SSRI-induced emotional blunting is a recognised, common iatrogenic cause of reduced pleasure, and it deserves a conversation with a prescriber rather than silence.

What bad advice this protects against, in all directions:
• "You're just lazy / unmotivated / not trying" → anhedonia is a measurable reward-circuit deficit (causally demonstrated by a dopamine agonist cutting it in a placebo-controlled trial, with a more pronounced effect on anhedonia than on broad depression); moralising it sends a treatable problem untreated.
• "Do a dopamine detox and your pleasure will reset" → the chemistry is a myth (you cannot fast a constitutive neurotransmitter and there is no receptor "reset"), so do not sell it as one. But the methodology underneath has genuine merit: cutting high-spike, low-effort supernormal inputs and restoring effortful reward is a real lever for reward re-learning. Keep the method, drop the name (see dopamine_motivation_baseline).
• "Just savor more / think positive" → savoring is a real but modest adjunct lever, not a standalone cure; positive-psychology interventions shrink to small effects once small-study bias is corrected.
• "Your meds broke you, come off them" → SSRI blunting is real and worth raising with a prescriber, but Realised never advises stopping or changing medication; abrupt discontinuation carries its own discontinuation and relapse risk.
• "It's just depression by another name, the SSRI will fix it" → anhedonia is dopaminergic and opioidergic more than serotonergic, predicts POOR SSRI response, and can even be dampened by serotonergic tone; treating it as generic depression misses it.

It does not own the dopamine-detox myth in full (dopamine_motivation_baseline owns the detox debunk and motivation neurochemistry) or the behavioural-activation protocol mechanics (behavioural_activation_for_depression owns those). It owns the recognition of anhedonia and the reward-rebuild stance.

Evidence

1. Anhedonia is transdiagnostic and maps onto separable reward-circuit deficits (Strong, existence claim). A functional neuroimaging ALE meta-analysis (Zhang et al. 2016, PMC4838562) found consummatory anhedonia (the "liking" deficit) tracks decreased ventral basal-ganglia activation, while anticipatory anhedonia (the "wanting" deficit) tracks frontostriatal circuitry, with dopamine implicated in wanting rather than liking. A separate transdiagnostic VBM study (Neuroimage: Clinical, 2021, PMC8455863) adds a structural layer, implicating putamen (dorsal striatum) and cerebellar volumetric abnormalities as a shared substrate (it did NOT find a ventral-striatum dissociation). Together these are the receipt for "real and measurable": the symptom has a brain-circuit signature, it is not a character flaw, and it shows up across depression, burnout, post-viral states, and chronic stress rather than belonging to one diagnosis.

2. A dopamine agonist moved anhedonia more than it moved broad depression in a placebo-controlled RCT (Strong for the causal reward-circuit claim). The PRIME-PRAXOL trial of pramipexole for anhedonic depression (Nature Medicine, 2026; PMID 42286321) randomised 85 participants; the primary anhedonia endpoint (SHAPS) moved with Hedges' g = 0.62 (p = 0.006). Pramipexole also significantly improved depression across the trial (MADRS-S p = 0.012; HDRS-6 p = 0.0024); only the single week-9 MADRS-S endpoint was non-significant (g = 0.34, p = 0.13). So this is not a clean dissociation: the drug's effect was MORE PRONOUNCED for the motivational/anhedonic symptoms than for broad depressive symptoms, rather than hitting anhedonia and leaving depression untouched. Hitting the dopaminergic circuit moves anhedonia, which supports it being a reward-circuit problem, while the broader-but-weaker depression effect cautions against reading anhedonia as wholly separable from depression. (Note the funding caveat below: dopaminergic anti-anhedonia drugs are being commercialised, so the spin around this result is not neutral, though the trial itself was independently funded.)

3. Behavioural Activation has large effects on depression and improves activation, the mechanism most relevant to anhedonia (Strong for BA generally). Ekers et al. 2014 (PLOS One, PMC4061095): BA versus controls SMD −0.74 (k = 25, N = 1088), BA versus medication SMD −0.42. A cross-meta in Psychological Medicine reported BA versus inactive controls g = 0.83 for depression and g = 0.64 for activation. The activation effect matters because re-engaging with reward is the active ingredient anhedonia needs. The anhedonia-specific transfer is the weaker link, addressed next.

4. Behavioural Activation built FOR anhedonia (BATA) moves anhedonia substantially, but is NOT superior to an active comparator (Moderate, honest both-ways receipt). A parallel-arm RCT (Behaviour Research and Therapy, 2024; PMC11519751) compared BATA (n = 61) with mindfulness-based cognitive therapy (n = 55). Anhedonia (SHAPS) dropped −7.18 with a large within-condition effect (d = 1.69), but there was NO significant between-group difference on the primary anhedonia endpoint. Read honestly: anhedonia clearly improves with structured behavioural treatment, but the gain is partly non-specific (common-factor) rather than proof that one branded protocol is special. This is why the entry says "do the work," not "buy this protocol."

5. Positive Affect Treatment (savoring plus reward-focused CBT) beat standard negative-affect CBT, including on suicidal ideation (Strong, the strongest single therapy receipt for restoring positive affect). Craske, Meuret et al. 2019 (J Consulting & Clinical Psychology, PMID 30998048): RCT of N = 96, PAT versus Negative Affect Treatment; positive affect d = 0.52 (post) and 0.67 (6 months), depression d = 0.34, anxiety d = 0.30, and suicidal ideation 1.7% versus 12.0% at 6 months (p < 0.001). Replicated in 2023. This targets the reward deficit directly and is the clearest evidence that you can rebuild consummatory pleasure rather than wait for it to return.

6. Anhedonia predicts POOR response to standard SSRIs (Moderate, clinically load-bearing). Int J Neuropsychopharmacology 2024 (Oxford, pyae055) links anhedonia to a specific depression profile and poor antidepressant response. A Serretti 2025 review (Psychiatry Clin Neurosci Reports) reports anhedonia improving less on SSRIs than on agomelatine and dopaminergic agents. The mechanism is that anhedonia is dopaminergic and opioidergic rather than primarily serotonergic, and SSRIs can dampen dopaminergic tone. (Caveat: agomelatine and vortioxetine carry branded anhedonia-superiority marketing, so discount the "our drug is better" framing in industry-adjacent reviews; the load-bearing claim here is only that SSRIs underperform on anhedonia, not that any specific branded drug wins.)

7. SSRI / antidepressant emotional blunting is common, around half of treated currently-depressed patients (Moderate for existence, softer on magnitude). Goodwin et al. 2017 (J Affective Disorders, PMID 28628765): survey of N = 669 on SSRI or non-SSRI monotherapy found emotional blunting in 46% overall (men 52%, women 44%). Goodwin also found OQESA blunting scores correlated with depression severity and concluded blunting is PARTLY a residual symptom of depression rather than purely an antidepressant side-effect, so this 46% should not be read as a clean iatrogenic prevalence. Selected SSRI samples report apathy as high as ~92%. The prevalence figure is survey-grade and soft, but the phenomenon's reality is well-established. This is a plausibly iatrogenic contributor to anhedonia that patients are rarely warned about. (The Goodwin survey had pharma-adjacent author networks, and disclosing blunting can serve drug-switching marketing, so the number is reported as a range, not a hard fact.)

8. Whether blunting is a drug effect or residual depression is genuinely contested (Emerging, unresolved counter-receipt). A Frontiers in Psychiatry 2021 non-systematic review (PMC8712545) found blunting correlates with higher residual depression scores, suggesting partial residual-symptom origin, while patients describe it as qualitatively distinct, emerging after treatment starts and persisting as mood improves. The attribution is not settled. This receipt is included deliberately so the entry does not over-blame SSRIs. (Reframing blunting as "residual depression" subtly favours staying on or intensifying medication, so this view is not bias-free either.)

9. Exercise is an effective, dose-relevant treatment for depression and a low-cost reward lever (Moderate). Noetel et al. 2024 (BMJ, PMID 38806193): a network meta-analysis of RCTs found walking or jogging, yoga, and strength training showed the greatest effects versus controls, with larger effects for more vigorous modalities. The paper carries a published correction on effect-size calculation, high heterogeneity, and blinding limits, so cite the magnitudes cautiously and treat the anhedonia-specific effect as extrapolated from depression. (Counter-incentive: the fitness industry over-sells exercise as a panacea; temper the claim.)

10. The "dopamine detox / fasting resets pleasure" framing is neurochemically incoherent (Strong against the myth). Expert commentary (The Scientist 2022, "Debunking the Dopamine Detox Trend," indexed by NLM; Psychology Today clinicians 2020) is consistent: dopamine spans at least five pathways and several receptor types, it is not a quantity that depletes and refills, and abstaining from pleasure does not reset levels. Any benefit from a "detox" comes from reduced overstimulation and behaviour change, not from a receptor reset. (This entry references rather than re-argues the myth; dopamine_motivation_baseline owns the full debunk.)

11. "Supernormal stimuli" plausibly flatten ordinary rewards, but on mechanism, not RCTs (Emerging to Experimental). The concept ("Hijacked by the Feed," a 2025 narrative review in Cureus, PMC12042983; Tinbergen-derived supernormal-stimulus theory) argues that hyper-concentrated digital rewards (endless feeds, on-demand hyper-palatable reward, porn) raise the comparison bar so ordinary rewards feel flat. The source is a single narrative/opinion review in a low-rigor, author-pays journal, so this is mechanism, not evidence: it rests on conceptual argument rather than any controlled human reward-sensitivity trial. Present it as a hypothesis worth acting on cheaply, not an established cause. (Cui bono both ways: the "digital detox" industry profits from the desensitisation story; platforms profit from denying it.)

12. Savoring and positive-psychology interventions are small, not hero, effects (Moderate, deflating counter-receipt). White, Uttl and Holder 2019 (PLOS One, 14(5):e0216588; PMID 31141537): re-analysing the positive-psychology meta-analytic literature with small-sample-bias correction, they conclude positive-psychology-intervention effects are much smaller than previously reported, and depression effects in particular are variable and generally non-significant once that bias is corrected (the often-cited r ≈ 0.10 well-being figure is from Bolier et al., cited within White, not White's own headline result). So "just savor more" is not a standalone cure; savoring is a real but modest lever, best used as an adjunct (for example inside PAT).

Mechanism

Wanting, liking, and learning are separable, and they break separately. Reward is not one process. Anticipatory reward ("wanting," the drive to pursue) runs through frontostriatal and dopaminergic circuitry; consummatory reward ("liking," the in-the-moment pleasure) runs more through ventral basal-ganglia and opioidergic signalling; and reward learning binds outcomes to actions. Anhedonia can hit any of these, which is why a person can still "want" things abstractly but feel nothing when they arrive, or feel no pull to start at all. This is also why the dopamine-centric folk model is wrong: dopamine drives wanting, not liking, so "more dopamine" does not restore pleasure.

Why behaviour rebuilds the circuit. Reward learning is experience-dependent. When a depressed or burned-out person withdraws, the circuit gets fewer reward signals to learn from, the "nothing is worth it" prediction goes unchallenged, and the deficit deepens. Behavioural activation and graded reward exposure work by feeding the system small, scheduled, completed rewards (do-before-you-feel), which re-supply the prediction error the circuit needs to relearn that action leads to reward. This is re-learning, not "resetting." Savoring extends the same logic to consummatory pleasure: deliberately attending to and prolonging a positive experience strengthens the liking signal that anhedonia has dampened.

Why "you can't fast dopamine" is literally true. Dopamine is a constitutive neurotransmitter, continuously synthesised and required for ordinary movement, attention, and motivation. It is not a battery that drains with pleasure and recharges with abstinence. Sitting in a dark room avoiding fun does not lower a "dopamine level" you then bank. Where a "detox" helps at all, it is because you stopped competing your ordinary rewards against artificially concentrated ones, which is a behavioural and comparative effect, not a receptor reset.

Why supernormal stimuli flatten the ordinary (hypothesis). A supernormal stimulus is an exaggerated version of a natural reward that captures the system more strongly than the real thing. Endless-scroll feeds and on-demand hyper-reward deliver intensity and novelty that ordinary life cannot match, which can plausibly raise the brain's comparison bar so a walk, a meal, or a conversation registers as flat. The mechanism is reasonable; the human evidence is thin, so Realised treats reducing supernormal load as a cheap, low-risk experiment, not a proven cure.

Why anhedonia resists SSRIs. SSRIs raise serotonergic tone. Anhedonia is driven more by dopaminergic and opioidergic reward signalling, and serotonergic tone can actually dampen dopaminergic output. So the drug class that helps the negative-affect side of depression (low mood, anxiety) can leave the reward deficit untouched or, via emotional blunting, blunt the highs along with the lows. That is the mechanistic reason anhedonia predicts poor SSRI response and why naming blunting as a possibility matters.

Risks And Contraindications

• Anhedonia is a leading predictor of suicidality. In the PAT trial, suicidal-ideation probability was 12.0% versus 1.7% at follow-up. Persistent or severe anhedonia must route to professional help, and this entry must never position behavioural self-help as a substitute for treatment in moderate-to-severe depression.
• Never advise stopping or changing an SSRI. The blunting caveat is "a recognised side effect worth raising with your prescriber," framed to avoid abrupt discontinuation. Stopping an SSRI suddenly carries discontinuation syndrome and relapse risk; that decision belongs to the prescriber.
• Do not over-claim any single intervention. BATA showed no superiority over an active comparator (MBCT), and pramipexole's effect was more pronounced for anhedonia than for broad depression rather than a clean dissociation. No single behavioural protocol or drug is a cure; the honest claim is that several levers reliably move the symptom.
• The supernormal-stimulus / "digital anhedonia" link is a hypothesis. It is mechanistically plausible but RCT-thin. Reducing feed load is low-risk and worth trying, but do not present it as an established cause or a guaranteed cure, and do not let "digital detox" fear become its own moral panic.
• Savoring is an adjunct, not a hero. Selling "just savor more" as a standalone fix is the positive-psychology industry's over-claim; corrected effects are small. Use it inside a structured plan.

Controversy

Nature of the controversy: a real, treatable brain-circuit phenomenon collides with a viral but false consumer model, and there is a second live dispute about whether blunting blames the drug or the disease. Error sits at both poles, over-medicalising into a "dopamine reset" purchase, and dismissing the symptom as laziness or as nothing more than ordinary depression.

Position A — "Anhedonia is a real reward-circuit dysfunction you can rebuild." The clinical-neuroscience take.
• Best evidence: separable wanting/liking/learning deficits with a striatal and frontostriatal functional signature (Zhang et al. 2016, PMC4838562), with a structural correlate in putamen/cerebellum (PMC8455863); a dopamine agonist moving anhedonia more than broad depression in a placebo-controlled RCT (PRIME-PRAXOL, SHAPS g = 0.62); behavioural treatments (BA, PAT, exercise) moving anhedonia and positive affect in RCTs.
• Where it must stay honest: BATA was not superior to an active comparator, so part of the benefit is non-specific; the supernormal-stimulus story is mechanism, not trial-proven; and dopaminergic-drug developers have an incentive to amplify the "reward-circuit, our drug fixes it" framing.

Position B — "Dopamine detox / fasting will reset your pleasure, and anhedonia is basically just stress or depression." The consumer-wellness take, plus the reflexive-dismissal take.
• Best evidence: a lot of low pleasure genuinely is downstream of overstimulation, poor sleep, and stress, all behavioural; and reducing screen and hyper-reward load does often help.
• Where it's wrong: you cannot fast a constitutive neurotransmitter, there is no receptor reset, and the help that does come is from behaviour change and reduced competition, not "detoxing dopamine." Treating anhedonia as generic depression also misses that it predicts poor SSRI response and is dopaminergic, not primarily serotonergic.

The funding picture — cui bono, both ways. On the pro-treatment and pro-pharma side, Alto Neuroscience and others are commercialising dopaminergic anti-anhedonia drugs (ALTO-207, pramipexole plus ondansetron, Phase 2b expected 2027) and amplify favourable trials; agomelatine and vortioxetine carry branded anhedonia-superiority claims, so "SSRIs are bad for anhedonia, our drug is better" reviews are not neutral. PAT and BA manuals are sold commercially, a mild incentive, though their trials are publicly funded and replicated. On the contrarian and wellness side, the dopamine-detox and digital-detox economy (books, apps, retreats, influencer programmes) profits directly from the false receptor-reset narrative and from "digital anhedonia" fear, while social-media platforms profit from denying that their feeds are supernormal stimuli. The reward-circuit reality and the behavioural-rebuild levers survive scrutiny on both incentive axes; the dopamine-reset myth is sold, not science.

Realised Position: Treat anhedonia as a reward-circuit problem you rebuild, not a dopamine tank you drain and refill. The evidence-based levers are behavioural and re-learning-based: behavioural activation and graded reward exposure (do-before-you-feel), savoring and positive-affect practice to restore consummatory pleasure, and exercise, all with moderate, replicated support. Reducing supernormal-stimulus load is reasonable because it lowers the comparison bar for ordinary rewards, NOT because it "detoxes dopamine." If anhedonia or blunting started or worsened after an SSRI, name it as a recognised, common possibility worth discussing with the prescriber; Realised does not tell anyone to stop medication, but it refuses to let an iatrogenic cause go unnamed. And persistent or severe anhedonia routes to professional help, because it is a leading predictor of suicidality, not a self-help project.

Cross-Pillar Connections

• Mental (behavioural_activation_for_depression): owns the behavioural-activation protocol mechanics this entry points at; this entry owns recognising anhedonia and the reward-rebuild stance, and hands the "how to run BA" detail there.
• Mental (depression_lifestyle_interventions): the broader lifestyle-treatment context for depressed mood; anhedonia is the reward-specific symptom within it, and routes back when the picture is full depression rather than isolated reward loss.
• Physical / Mental (exercise_for_mood_dose_response): owns the exercise-for-mood dose-response detail; this entry flags exercise as a reward lever and defers the dosing there.
• Mental / cross-pillar (supernormal_stimuli_digital_recovery): owns the digital-overstimulation and recovery story; this entry cites it for the "lower the comparison bar" lever rather than asserting the causal "digital anhedonia" claim itself.
• Mental (burnout_physiology_and_recovery): burnout is a common non-depressive home for anhedonia; that entry owns the burnout physiology, this one owns the reward-loss symptom that shows up inside it.
• Sleep / Mental (sleep_mood_connection): poor sleep flattens reward and mood and is a frequent upstream contributor; route there when sleep is the likely driver of the flatness.

What would change our mind

Industry bias note

Sources (14)

• Zhang et al. (2016). Functional ALE meta-analysis of reward processing in anhedonia. PMC4838562. (Independent/academic.) — consummatory anhedonia → decreased ventral basal-ganglia activation; anticipatory → frontostriatal; dopamine in "wanting," not "liking."↗
• Transdiagnostic VBM study of anhedonia (2021). Neuroimage: Clinical. PMC8455863. (Independent/academic.) — structural/volumetric abnormalities in putamen (dorsal striatum) and cerebellum as a shared transdiagnostic substrate; did NOT find a ventral-striatum dissociation.↗
• PRIME-PRAXOL RCT, pramipexole for anhedonic depression (2026). Nature Medicine. pubmed.ncbi.nlm.nih.gov/42286321↗/" target="_blank" rel="noopener">PMID 42286321↗. (Independently funded by university investigators; note commercial amplification by dopaminergic-drug developers.) — N = 85; SHAPS anhedonia g = 0.62 (p = 0.006); depression also significantly improved (MADRS-S p = 0.012; HDRS-6 p = 0.0024), with only the single week-9 MADRS-S endpoint non-significant (g = 0.34, p = 0.13); effect more pronounced for anhedonia than broad depression, not a clean dissociation.
• Ekers D, et al. (2014). Behavioural activation meta-analysis. PLOS One. PMC4061095. (Publicly/academically funded; BA is non-proprietary.) — BA vs controls SMD −0.74 (k = 25, N = 1088); BA vs medication SMD −0.42; cross-meta g = 0.83 depression, g = 0.64 activation.↗
• Behavioural Activation for Anhedonia (BATA) parallel-arm RCT (2024). Behaviour Research and Therapy. PMC11519751. (NIMH-funded; no drug sponsor.) — BATA n = 61 vs MBCT n = 55; SHAPS −7.18, within-condition d = 1.69, but NO significant between-group difference on the primary anhedonia endpoint.↗
• Craske MG, Meuret AE, et al. (2019). Positive Affect Treatment RCT. J Consulting & Clinical Psychology. pubmed.ncbi.nlm.nih.gov/30998048↗/" target="_blank" rel="noopener">PMID 30998048↗. (Academic, UCLA/SMU; PAT manual published commercially — mild incentive — but design rigorous and replicated 2023.) — N = 96; positive affect d = 0.52 (post) / 0.67 (6mo); depression d = 0.34; anxiety d = 0.30; suicidal ideation 1.7% vs 12.0% at 6mo (p < 0.001).
• Anhedonia and antidepressant response (2024). Int J Neuropsychopharmacology (Oxford), pyae055; Serretti (2025) review, Psychiatry Clin Neurosci Reports. (Some pro-dopaminergic / pro-agomelatine framing in industry-adjacent reviews — discount branded-superiority claims.) — anhedonia → specific depression profile and poor antidepressant response; improves less on SSRIs than on agomelatine/dopaminergic agents.↗
• Goodwin GM, et al. (2017). Emotional blunting survey. J Affective Disorders. pubmed.ncbi.nlm.nih.gov/28628765↗/" target="_blank" rel="noopener">PMID 28628765↗. (Pharma-adjacent author networks; disclosing blunting can serve switching-drug marketing.) — N = 669; emotional blunting 46% overall (men 52%, women 44%); apathy up to ~92% in selected SSRI samples; blunting scores correlated with depression severity, and Goodwin concluded it is partly a residual symptom of depression, not purely a drug side-effect.
• Emotional blunting attribution review (2021). Frontiers in Psychiatry. PMC8712545. (Non-systematic; reframing blunting as "residual depression" subtly favours continuing medication.) — blunting correlates with higher residual depression, suggesting partial residual-symptom origin; attribution unresolved.↗
• Noetel M, et al. (2024). Exercise for depression network meta-analysis. BMJ. pubmed.ncbi.nlm.nih.gov/38806193↗/" target="_blank" rel="noopener">PMID 38806193↗. (Academic; exercise non-commercial — but fitness industry over-sells exercise as panacea.) — walking/jogging, yoga, strength training largest effects; published correction on effect-size calculation; high heterogeneity — cite magnitudes cautiously.
• "Debunking the Dopamine Detox Trend" (2022). The Scientist (NLM-indexed commentary, Sapolsky/clinicians); Psychology Today (2020) "Debunking Dopamine Fasting." (Academic-backed debunk; little commercial upside vs the detox-book/app economy.) — dopamine spans ≥5 pathways/receptor types; abstinence does not reset levels.↗
• "Hijacked by the Feed" (2025). Cureus. PMC12042983; supernormal-stimulus concept (Tinbergen-derived). (Single narrative/opinion review in a low-rigor, author-pays journal — not controlled trials; "digital detox" industry and platforms have opposing incentives.) — supernormal stimuli plausibly flatten ordinary reward; mechanism, not RCT.↗
• White CA, Uttl B, Holder MD (2019). Positive-psychology interventions meta-analysis re-analysis. PLOS One 14(5):e0216588; pubmed.ncbi.nlm.nih.gov/31141537↗/" target="_blank" rel="noopener">PMID 31141537↗. (Counters positive-psychology industry over-claiming.) — with small-sample-bias correction, PPI effects much smaller than previously reported; depression effects variable and generally non-significant once corrected (the r ≈ 0.10 figure is Bolier et al., cited within White, not White's own headline).
• Funding notation: the load-bearing anchors (reward-circuit neuroimaging, the independently-funded agonist RCT, BA/PAT/exercise trials) are academic and largely publicly funded; the strongest deflating receipts (the BATA active-comparator null, the corrected-down positive-psychology effects, the contested blunting attribution) run against any single commercial interest. Where industry incentive is present — dopaminergic-drug developers, branded-antidepressant reviews, and the detox/digital-detox economy — it is flagged inline and discounted.*↗

Related entries